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ABSTRACT:
Genetically engineered mouse models (GEMMs) of human cancer are important 
for advancing our understanding of tumor initiation and progression as well as for 
testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing 
retina that initiates with biallelic inactivation of the RB1 gene. GEMMs faithfully 
recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical 
and neurochemical features of human retinoblastoma. In this study, we analyzed 
the genomic and epigenomic landscape of murine retinoblastoma and compared 
them to human retinoblastomas to gain insight into shared mechanisms of tumor 
progression across species. Similar to human retinoblastoma, mouse tumors have low 
rates of single nucleotide variations. However, mouse retinoblastomas have higher 
rates of aneuploidy and regional and focal copy number changes that vary depending 
on the genetic lesions that initiate tumorigenesis in the developing murine retina. 
Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly 
different from human tumors and some pathways that are candidates for molecular 
targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated 
in GEMMs. Taken together, these data suggest there are important differences 
between mouse and human retinoblastomas with respect to the mechanism of tumor 
progression and those differences can have significant implications for translational 
research to test the efficacy of novel therapies for this devastating childhood cancer. 
INTRODUCTION
Retinoblastoma is a rare childhood cancer of 
the developing retina that initiates with biallelic loss 
of the RB1 gene [1]. RB1 inactivation confers limitless 
replicative potential to retinoblasts and these preneoplastic 
cells can progress to retinoblastoma by acquiring 
additional cellular properties including evasion of 
cell death and senescence, sustained angiogenesis and 
activation of growth-signaling pathways. Several different 
mechanisms have been proposed to explain the rapid 
progression of retinoblastoma following RB1 inactivation. 
In a series of elegant studies using genetically engineered 
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murine cells and immortalized human cells, it was shown 
that RB1 plays an important role in maintaining genomic 
stability [2-4]. Thus, in some cellular contexts, inactivation 
of the RB1 gene could lead to chromosome instability 
(CIN), allowing secondary and tertiary mutations in key 
cancer pathways to be rapidly acquired. Alternatively, 
RB1 has also been implicated in a variety of epigenetic 
processes (reviewed by [5]) so it is also possible that 
perturbations in the epigenetic landscape may contribute 
to tumorigenesis in the retina. In support of an epigenetic 
mechanism, recent whole-genome sequencing and 
integrated epigenetic analysis of human retinoblastoma 
revealed that the tumors have relatively stable genomes 
and several cancer genes were epigenetically deregulated. 
At least one of those epigenetically deregulated genes 
(SYK) is required for retinoblastoma tumor cell survival 
in vivo [6].  These two alternative mechanisms (genome 
instability and epigenetic deregulation) of retinoblastoma 
progression are not necessarily mutually exclusive and 
some tumors may show evidence of both chromosomal 
instability and epigenetic deregulation.  
Over the past 8 years, a series of knockout mouse 
models of retinoblastoma have been generated by 
conditionally inactivating multiple Rb family members 
in the developing retina [7-9]. Knockout mouse models 
of retinoblastoma have been valuable for studying the 
contribution of other tumor suppressor pathways such 
as the p53 pathway [8] and for testing novel therapeutic 
agents for the treatment of retinoblastoma [10, 11].  In 
one study, 6 different strains of mice that develop 
retinoblastoma were analyzed side-by-side using the same 
retinal progenitor specific Cre transgene (Chx10-Cre)[9]. 
Histopathological analysis, gene expression profiling, 
morphometric, neuroanatomical and neurochemical 
analyses [9] showed that mouse retinoblastomas faithfully 
recapitulate the molecular and cellular features of 
human retinoblastomas.  However, while the timing of 
retinoblastoma initiation was indistinguishable across the 
6 strains, tumor penetrance and the rate of progression 
varied dramatically [9]. These data raise the possibility 
that the genetic/epigenetic changes that accompany 
human retinoblastoma progression may not be faithfully 
recapitulated in the mouse despite the remarkable inter-
species similarities at the molecular and cellular level. 
This could have important implications for interpreting 
preclinical testing of novel molecular targeted therapeutics 
in murine models of retinoblastoma. In fact, preclinical 
testing of combination chemotherapy (etoposide, 
carboplatin and vincristine) showed dramatic differences 
in response between genetically engineered mouse models 
(GEMMs) and human orthotopic xenografts; virtually all 
of the GEMMs were cured of their disease while there 
was no improvement in progression free survival or 
overall survival in the orthotopic xenograft model [12]. 
It is possible that such species-specific differences could 
be further amplified when testing molecular targeted 
therapeutics directed toward processes important for 
maintaining genomic stability or the epigenetic landscape 
of retinoblastoma.
In this study, we characterized the genomic and 
Figure 1: Analysis of DNA Content in Mouse and Human Retinoblastoma. (A) Survival curves for the three strains of mice 
used in this study. (B) Representative image of a late stage tumor from an RbTKO mouse showing anterior chamber invasion (arrow). (C) 
Quantitative analysis of DNA content for mouse retinoblastoma tumors taken directly from the mice (Rb TKO, p53 TKO and MDMX) 
as well as a mouse retinoblastoma cell line (SJmRBL8 and a control wild type MEF (wt)). (D) Quantitative analysis of DNA content for 
human retinoblastoma cell lines (Y79, Weri1, RB355), two orthotopic xenografts (SJRB001X and SJRB002X) and Tert immortalized 
fibroblasts as a normal diploid control (BJ).
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epigenomic landscape of murine retinoblastoma and 
provide a direct comparison to human retinoblastoma. 
Genome stability was measured by ploidy and gross 
chromosomal rearrangements (GCR). To explore the 
underlying mechanisms, we measured sister chromatid 
cohesion, kinetics of double strand DNA (dsDNA) 
damage repair, oxidative stress and expression of proteins 
implicated in maintenance of genome stability across 
species. In order to identify any possible secondary or 
tertiary genetic lesions in mouse retinoblastomas, we 
also performed array comparative genome hybridization 
(aCGH) and exome sequencing. Finally, to characterize 
the epigenetic landscape in mouse retinoblastoma we 
performed integrated analysis using gene expression 
data, DNA methylation data and analysis of histone 
marks associated with active or silent chromatin. Taken 
together, these data suggest that even though the overall 
molecular and cellular features of mouse and human 
retinoblastomas are remarkably similar, there are critical 
differences in the genomic and epigenomic landscapes 
across species. This may suggest that not only are the 
effects of RB1 inactivation cell-context specific but they 
may also be species specific.  These data have important 
implications for our understanding of the role of RB1 in 
tumorigenesis, for modeling human cancer in the mouse 
and for interpreting preclinical data using GEMMs and 
human orthotopic xenografts.
RESULTS
Conserved Gene Expression Signature in Mouse 
and Human Retinoblastoma
 We compared primary mouse tumors from three 
different strains (Fig. 1A-B) to human retinoblastoma 
to establish if any of these GEMMs recapitulates 
human retinoblastoma gene expression more closely. 
RbTKO mice (Chx10-Cre;RbLox/Lox;p107–/–;p130Lox/Lox) 
have mosaic conditional inactivation of all 3 Rb family 
members in retinal progenitor cells during development 
[9]. p53TKO mice (Chx10-Cre;RbLox/Lox;p107–/–;p53Lox/
Lox) combine Rb pathway inactivation with p53 pathway 
inactivation [7-9]. While the TP53 gene is not mutated 
in human retinoblastoma [8], these mice serve as a 
convenient positive control for our studies because p53 
gene inactivation can lead to defects in DNA repair and 
contribute to genome instability [13, 14]. MDMX mice 
(Chx10-Cre;RbLox/Lox;p107–/–;MDMXTg) have conditional 
overexpression of the MDMX gene to mimic the elevated 
expression of MDMX (Mdm4) in human retinoblastomas 
[8]. To determine the statistical significance of the 
similarity between the gene expression profiles of mouse 
and human retinoblastomas, we ran the agreement of 
differential expression (AGDEX) analysis using tumor 
and normal retina gene expression array data [15]. The 
differential expression statistics for the mouse comparison 
and human comparison for each of the 79,361 probe-set 
pairs for RbTKO, p53TKO and MDMX model is plotted in 
Supplemental Figure 1. We also computed the agreement 
statistics and P-values for each gene-set. A respective 
totals of 66, 16 and 20 gene-sets for RbTKO, p53TKO 
and MDMX models had the robust result of showing 
significance at the P = 0.01 level in each of the four 
permutation tests performed by computing each of two 
agreement statistics across permutations of group labels for 
each of two agreement statistics (Sup. Table 1). Overall, 
68.8% of 13,823 ortholog probe pairs in RbTKO, 71.2% 
of 11,273 ortholog probe pairs in MDMX, and 69.6% of 
11,059 ortholog probe pairs in p53TKO showed agreement 
in gene expression (upregulation or downregulation) 
between human retinoblastoma and the respective mouse 
counterpart (Sup. Table 1). These data are consistent with 
previous molecular, cellular, histopathological, electron 
microscopic, morphometric and neuroanatomical studies 
showing that the RbTKO, MDMX and p53TKO mouse 
retinoblastomas are indistinguishable [9]. The agreement 
of differential expression observed for the three genetic 
mouse models compared to human retinoblastoma, is 
higher than what was previously reported for genetic 
mouse models of medulloblastoma considered to be a 
Table 1: Results from SKY analysis for mouse retinoblastoma
Sample Cells scored 1Chr count 2del (%) 3gains (%) 4total aneuploidy (%)
p53TKO 23
36(1), 39(2), 40(8), 41(1), 44(1), 45(1), 
60(1), 71(1), 72(1), 78(1), 80(2), 83(1), 
84(1), 100(1)
43.5 47.8 65.2*
MDMX 13 43(6), 44(7) 0 100 100*
RbTKO 24 38(2), 39(1), 40(20), 42(1) 16.7 8.3 20.8
1Chromosomal count per cell, the number in parenthesis represents the number of cells that present the indicated chromosomal event 2del=percentage of cells with chromosomal deletions3gains=percentage of cells with chromosomal gains4percentage of cells presenting aneuploidy (chromosomal gains or deletions)*p>0.001 compared to RbTKO
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benchmark of GEMMs in pediatric cancer [16].
Analysis of DNA Content and Ploidy in Human 
and Mouse Retinoblastoma
As a first step toward determining if mouse 
retinoblastomas have defects in chromosome segregation 
that may lead to aneuploidy and change in DNA content, 
we performed FACS analysis of DNA content of mouse 
and human retinoblastoma cell lines, primary tumors 
and orthotopic xenografts. We used mouse embryonic 
fibroblasts (MEFs) as normal diploid control for mouse 
retinoblastoma and TERT-immortalized human fibroblasts 
(BJ) as a diploid control for human retinoblastoma [17]. 
All analyses were performed side-by-side to obtain 
quantitative comparisons across samples. Primary 
retinoblastomas from each of the GEMMs strains 
showed changes in overall DNA content as compared 
to the diploid control (Fig. 1C). A previously developed 
mouse retinoblastoma cell line (SJmRBL8) [18] also 
showed evidence of changes in DNA content consistent 
with aneuploidy (Fig. 1C). In contrast to these results 
Figure 2: Analysis of Sister Chromatid Cohesion in Mouse Retinoblastoma. (A) Representative image of DAPI-stained 
chromosome spread from a retinoblastoma in the MDMX mouse strain (Chx10-Cre;RbLox/Lox;p107–/–;MDMXTg). (B–E) Representative 
tracing showing the relative fluorescence intensity across 5 pairs of sister chromatids for mouse diploid fibroblasts (MEF) and primary 
mouse MDMX retinoblastoma cells after 4-hr or 20-hr colcemid treatments. Distance between the peaks is plotted in pixels. (F-I) Histogram 
of the number of chromosomes with the indicated sister chromatid distance is plotted for MEF, RBTKO, MDMX and p53TKO samples 
after 4-hr or 20-hr colcemid treatments. The mean and standard deviation were calculated from the indicated number of measurements 
from 3 independent experiments. * p values relative to MEF controls. (J) Examples of micronuclei and nuclear bridges in p53TKO mouse 
retinoblastoma. Scale bar: 5µm.
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from mouse retinoblastomas and cell lines, human 
retinoblastoma cell lines [19] and orthotopic xenografts 
[9] showed no deviation from the normal distribution in 
DNA content as compared to the diploid control (Fig. 1D). 
These data are consistent with the previously published 
data showing that most retinoblastomas have a diploid or 
near-diploid karyotype [20].  
To extend and validate the results from the FACS 
analysis, we performed spectral karyotype analysis (SKY) 
on primary tumors from each of the 3 mouse strains and 
both human orthotopic xenografts (Sup. Fig. 2, Tables 
1, 2). Overall, the mouse retinoblastomas exhibited 
aneuploidy but had no evidence of other types of GCRs 
(i.e. translocations, isochromosomes, and double minute 
formation) based on the SKY analysis (Sup. Fig. 2, 
Table 1). Interestingly, there was a significantly broader 
distribution of chromosome number in the p53TKO 
retinoblastoma tumors than MDMX and RbTKO 
retinoblastomas (Table 1). Moreover, statistical analysis 
of the SKY data showed that the RbTKO retinoblastomas 
had the highest probability of retaining a normal 
karyotype (retention probability=0.4773) (Sup. Table 2). 
In contrast, aneuploidy was less prevalent in the human 
retinoblastoma samples (retention probability=0.75) but 
there was evidence of other types of GCRs (Sup. Fig. 2, 
Table 2, Sup. Table 2). 
DNA content analysis and SKY provide quantitative 
data on chromosomal content and integrity at a single 
timepoint in individual cells but cannot distinguish 
between an acute event that leads to changes in 
chromosomal ploidy or stability [21] versus continuous 
defects in chromosome segregation. To test this directly, 
we analyzed clones of cells derived from individual 
mouse and human retinoblastoma cells. Primary human 
and mouse retinoblastomas do not grow from single cells 
in culture so we used the Y79 human retinoblastoma 
cell line (Sup. Fig. 3A,B) and the SJmRBL8 mouse 
retinoblastoma cell line (Sup. Fig. 3C,D) [18, 22]. Single 
cells were seeded into individual wells of 96 well dishes 
and 3 individual clones for each cell line were expanded. 
We karyotyped 20 cells for each clone and the parental cell 
lines and scored the number of chromosomal gains and 
losses (Sup. Fig. 3E). We found that there was more intra-
clonal heterogeneity in the mouse retinoblastoma cell line 
clones than in the human retinoblastoma cell line clones 
(Sup. Fig. 3E). 
Analysis of Sister Chromatid Cohesion in Mouse 
Retinoblastomas
Several studies in mice and cultured cells have 
linked RB1 inactivation to defects in chromosome 
segregation that can contribute to tumor cell aneuploidy 
[2, 3, 23-25] and CIN [2]. Specifically, in cultured human 
Table 2: SKY Analysis for Human Retinoblastoma Xenografts
1Sample Cells scored
2Chr count
3gains
(%)
4del
(%)
5Total 
aneuploidy (%)
6i(6)(p10) 
(%)
7der 
(%)
8dmin 
(%)
9dup 
(%)
10t 
(%)
SJRB001X 24 44(1), 45(2), 46(3), 47(18) 0 25 25 100 8.3 83.3 0 0
SJRB002X 
(2R.1) 15 47(15) 0 0 0 100 100 0 0 0
SJRB002X 
(4R.1) 8 46(1), 47(7) 0 0 0 87.5 100 0 12.5 0
SJRB002X 
(80R.1) 13 45(3), 46(10) 0 100 100 100 100 0 0 0
SJRB002X 
(2R.2) 15 47(15) 0 0 0 100 100 0 0 0
SJRB002X 
(4R.2) 14
45(5), 46(1), 
47(8) 0 42.9 42.9 100 100 0 0 7.1
SJRB002X 
(80R.2) 15 46(13), 47(2) 0 87 87 100 100 0 0 0
1The designations in parentheses indicate individual sublines (2R, 4R, 80R) and passage (2R.1 is passage 1 and 2R.2 is passage 2).
2 Chromosomal count per cell, the number in parenthesis represents the number of cells that present the indicated chromosomal event 
3gains=percentage of cells with chromosomal gains
4del=percentage of cells with chromosomal deletions
5percentage of cells presenting aneuploidy (whole chromosome gains or deletions)
6i=percentage of cells with isochromosome
7der=percentage of cells with derivative chromosomes
8dmin=percentage of cells with double minutes
9dup=percentage of cells with duplication
10t=percentage of cells with translocations
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Figure 3: Analysis of dsDNA-Break Repair in Retinoblastoma. (A) Comet analysis of retinoblastoma cell lines, human 
retinoblastoma xenografts, and primary mouse retinoblastoma tumors. The number of cells analyzed in each experiment is indicated at 
the top of the plot. TERT-immortalized human fibroblasts (BJ) were used as the normal human negative-control; MEF cells were used as 
the normal mouse negative-control, and Brca;p53-deficient medulloblastoma cells were used as the positive control. (B-G) Cells were 
exposed to 10 Gy irradiation (IR), and dsDNA-break repair of BJ and SJRB001X tumor cells (C, D), MEF, RbTKO and p53TKO tumor 
cells (E-G) was monitored by performing comet assays at different time points. (B) Representative images of nuclei stained with Sytox 
green before and after exposure to 10 Gy IR. (H) Immunostaining of primary human retinoblastoma to detect TP53BP1 foci (arrow). (I, J) 
Immunofluorescence detection of TP53BP1 (red) in DAPI-stained nuclei (blue) of untreated BJ and SJRB001X cells and after exposure 
to 5 Gy IR. Foci of TP53BP1 at sites of dsDNA breaks are highlighted with arrows. Histogram of the proportion of cells with TP53BP1 
foci before and after exposure to 5 Gy IR in (K) human retinoblastoma cell lines (Weri1 and Y79), (L) two independent retinoblastoma 
orthotopic xenografts (SJRB001X and SJRB002X), (M) mouse retinoblastoma cell line (SJmRBL8), and (N) the three primary mouse 
retinoblastoma (RBTKO, MDMX, p53TKO). p values compared to untreated samples. 
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RPE cells, RB1 knockdown results in a defect in sister 
chromatid cohesion that makes the chromatids more prone 
to separate when cells are delayed in mitosis [2]. Defects 
in sister chromatid cohesion can lead to aneuploidy and 
may, in turn, contribute to CIN by forming merotelic 
kinetochore attachments [26-28]. Previous studies have 
shown that human RB1-deficient retinoblastoma cells 
have defects in sister chromatid cohesion [6] consistent 
with previously published data on cultured human RPE 
cells with RB1 depletion [2]. To determine if changes 
in sister chromatid cohesion correlate with increased 
aneuploidy in mouse retinoblastoma cells, we analyzed 
the distance between sister chromatids in colcemid-
treated mouse retinoblastoma tumor cells from RbTKO, 
MDMX and p53TKO strains and the SJmRBL8 mouse 
retinoblastoma cell line. The mouse retinoblastoma cells 
had a significant increase in sister chromatid cohesion in 
all mouse retinoblastoma cells compared to MEF cells 
after 4 hr and 20 hr of colcemid treatment (p<0.01)  (Fig. 
2A–I and data not shown). In addition, there was a subtle 
increase in micronuclei and nuclear bridges in some of the 
retinoblastoma samples (Fig. 2J and Sup. Table 3). Overall, 
these data are consistent with previously published data 
on human retinoblastomas and RB1-depleted human RPE 
Figure 4: Mouse and Human Integrative Data Analysis for Retinoblastoma Integrative data analysis for mouse 
retinoblastoma was compared to the human retinoblastoma integrative data from Zhang et al[6]. (A) Diagram showing 
the number of genes significantly deregulated in mouse and human retinoblastoma, the subset considered epigenetically deregulated by our 
integrative data analysis in each specie and those epigenetically deregulated both in mouse and human. (B) Gene expression data of the 131 
genes epigenetically deregulated in the RbTKO mouse retinoblastoma model that could be matched to genes in the human retinoblastoma 
integrative data. (C) Gene expression data of the 111 genes epigenetically deregulated in human retinoblastoma that could be matched 
to genes in the RbTKO mouse retinoblastoma. Genes up- and down-regulated in both mouse and human are depicted in red and green, 
respectively. Genes deregulated in opposite directions are colored in gray. Genes found to be epigenetically deregulated in both species are 
labeled (black dots). (D) Proposed survival pathways for mouse and human retinoblastoma.
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cells showing that loss of RB1 leads to defects in sister 
chromatid cohesion [2]. 
Analysis of Chromosomal Lesions and Double 
Strand–Break Repair in Retinoblastoma
Tumor cells with high rates of dsDNA breaks or 
defects in dsDNA-break repair may accumulate GCRs 
such as translocations, inversions, double minutes and 
isochromosomes [29-31]. To test the integrity of the 
retinoblastoma genome directly, we performed comet 
assays on human and mouse retinoblastoma cell lines, 
mouse retinoblastoma tumors, and human retinoblastoma 
orthotopic xenografts. BJ (human) and MEF (mouse) cells 
were used as normal controls, and Brca2;p53 deficient 
murine medulloblastoma cells were used as a positive 
control because these cells have defects in dsDNA-break 
repair [32]. The DNA fragmentation of the Brca2;p53-
deficient cells was significantly increased compared to 
the wild type control cells (p<0.001, Fig. 3A). Human 
retinoblastoma cells as well as the mouse cell line 
SJmRBL8 and MDMX tumor cells were indistinguishable 
from the wild type control cells in this assay, but 
mouse RbTKO and p53TKO retinoblastoma cells had 
significantly higher basal levels of DNA breaks compared 
to the MEF control (p<0.001, Fig. 3A). 
Next, we induced sub-lethal levels of dsDNA breaks 
by exposing the cells to 10 Gy of ionizing radiation (IR), 
the minimum dose at which all cells showed a significant 
increase in dsDNA breaks using the comet assay. We 
monitored the integrity of the genome 30 minutes, 8 hours 
or 24 hours after exposure to 10 Gy IR (Fig. 3B-G and 
data not shown).  We found that control cells, human 
retinoblastoma cells and mouse MDMX and p53TKO 
retinoblastomas repaired DNA breaks within 8 hours, 
while RbTKO retinoblastomas failed to repair DNA 
damage even after 24 hours (p<0.001, Fig. 3C-G and data 
not shown). 
To complement the comet assays, we analyzed 
the focal accumulation and resolution of proteins that 
target dsDNA breaks (γ-H2AX and TP53BP1) in human 
and mouse retinoblastoma cells. First, we used a tissue 
microarray to analyze the expression pattern of TP53BP1 
on 90 primary human retinoblastomas (Fig. 3H) and 
found that a subset of primary human retinoblastomas had 
elevated endogenous levels of TP53BP1 nuclear foci (Sup. 
Table 4 and Fig. 4H) although the expression of TP53BP1 
and the number of chromosomal lesions detected was 
not correlated (data not shown). TP53BP1 expression on 
3 of each of the mouse retinoblastoma models was also 
analyzed and we found extensive endogenous levels of 
TP53BP1 nuclear foci in 100% of the samples analyzed 
(data not shown). 
Next, we analyzed the resolution of dsDNA breaks 
(γ-H2AX and TP53BP1 foci) in human and mouse 
retinoblastoma cells following exposure to 5 Gy IR. We 
used a lower dose of IR for these experiments than the 
previous comet assays in order to resolve the individual 
immunofluorescent γ-H2AX and TP53BP1 foci on 
confocal micrographs. Retinoblastoma cell lines, mouse 
tumors and the human orthotopic xenografts had slightly 
more basal γ-H2AX and TP53BP1 foci than did normal 
diploid control cells (Fig. 3I-N and data not shown). 
Treatment with 5 Gy IR led to an increase in the number 
of foci per cell, and these foci were largely resolved by 
24 hours for the human retinoblastomas (Fig. 3I-L). The 
kinetics of resolution of the dsDNA-break repair in human 
was similar to that of control cells. However, all mouse 
retinoblastoma cells displayed a significant reduction 
in their ability to resolve TP53BP1 foci over 24 hours, 
though p53TKO doesn’t reach statistical significance 
(p=0.2, Fig. 3M,N). 
Another source of stress that may contribute to 
aneuploidy and CIN in mouse retinoblastomas is oxidative 
stress [33]. Indeed, the spectrum of SNVs in human 
retinoblastoma whole genome sequence data are consistent 
with elevated levels of reactive oxygen species in the 
tumor cells [34]. To determine whether retinoblastomas 
have elevated levels of oxidative stress, we quantified 
reactive oxygen species by using the oxidation-sensitive 
dye DCF-DA in flow cytometry experiments (Sup. Fig. 
4). We found that mouse retinoblastoma cells had evidence 
of oxidative stress using this assay (Sup. Fig. 4 and data 
not shown).  Interestingly, when we measured the mouse 
and human retinoblastomas’ sensitivity to oxidative stress 
(i.e., H2O2 exposure) compared to that of our normal 
control cells (BJ and MEF), we observed a decrease in 
DCF-DA oxidation, except for mouse RbTKO (Sup. Fig. 
4). This decrease in DCF-DA oxidation correlated with a 
significant increase in cell death in tumors and could be 
reversed by treatment with antioxidants or catalase (Sup. 
Fig.4 and data not shown). These data suggest that some 
retinoblastomas are at their maximum tolerable oxidative 
stress levels (except RbTKO) and that this may contribute 
to elevated levels of dsDNA breaks and G-to-T or C-to-A 
transversions [6].
Analysis of Genetic Changes in Mouse 
Retinoblastoma 
Whole genome sequence analyses of human 
retinoblastoma showed a low rate of aneuploidy, structural 
variations (SVs) and copy number variations compared to 
tumors with chromosomal instability [6]. To determine 
if this low rate of chromosomal lesions is also found in 
mouse retinoblastomas and if the defects in dsDNA break 
repair contribute to increased rates of chromosomal lesions 
in the RbTKO mouse retinoblastomas, we performed 
aCGH analyses for 6 tumors of each of the mouse 
retinoblastoma models (Sup. Fig. 5). Gains or losses of 
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Figure 5: SYK Is Not Epigenetically Deregulated in Mouse Retinoblastoma. (A-D) Gene expression validation for a subset of 
genes downregulated (A, C) and upregulated (B, D) in mouse RbTKO tumors (A-B) and human retinoblastoma (C-D). In (A-B), control 
(c) is postnatal day 5 wilt type (P5 wt) mouse retina and tumor are three independent RbTKO retinoblastoma tumors. In (C-D), control is 
fetal week 20 normal retina and tumor are three independent primary human retinoblastomas. Data are presented as the mean and standard 
deviation of duplicate samples, and all are normalized to GPI1 expression relative to that of control retina. (E–H) ChIP validation for 
histone marks at the promoter region in mouse (E-F) and human (G-H) tumors using non-amplified ChIP DNA. Green indicates activating 
histone marks and red indicates repressive histone marks. Each bar is the mean and standard deviation of triplicate samples. (I) Immunoblot 
of SYK, MCL1, MDMX and actin from retinoblastoma cell lines and P5 wt control retinae. (J) Array-comparative genomic hybridization 
(aCGH) data for the MDMX gene in RBTKO, MDMX and P53TKO tumor samples.
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whole chromosomes were observed in approximately 
half of the tumors from each genotype (Sup. Table 5). 
In agreement with our previous SKY analysis, p53TKO 
tumors had an average of 3.83 chromosomal gains/losses 
compared to 0.67 for both RbTKO and MDMX tumors 
(p<0.1). A maximum of 10 chromosomal gains/losses 
were present in one of the p53TKO tumors (P53-169). 
The most common recurrent whole chromosome lesion 
was a gain of chromosome 12 across each of the mouse 
models (3/6 RbTKO, 2/6 MDMX, and 3/6 p53TKO) (Sup. 
Table 5). Chromosome 12 contains a region of synteny 
with human 14q, a chromosome including 14q32, a region 
for which translocations has been previously described in 
human retinoblastoma [20]. No copy number gains or 
epigenetic changes have been reported for genes in this 
region in human retinoblastoma.
In addition to whole chromosome gains and losses 
that are characteristic of aneuploidy, there were also 
several large recurrent chromosomal regions (≥3Mb) in 
a subset of tumors among RbTKO, MDMX and p53TKO 
(Sup. Table 6). The overall average number of gains or 
losses of large chromosomal regions (≥3Mb) was 1.83 
for RbTKO, 1.00 per MDMX and 0.50 per p53TKO 
and the maximum was 7 in a single tumor (TKO-841) 
(Sup. Table 6). In all tumor models, 66.7% (4/6) had no 
regional chromosomal gains or losses (Sup. Table 6). Of 
interest, we observed recurrent regional chromosomal 
lesions in chromosome 12 in regions of synteny to 
human chromosome 14q32 in 3/18 samples. In total, 55% 
(10/18) of mouse retinoblastomas had whole or regional 
chromosomal gains on chromosome 12.
A striking difference was observed in the number 
of focal lesions (20kb- 3Mb) in the RbTKO compared to 
MDMX and p53TKO (p<0.01).  On average, the RbTKO 
tumors had 176.2 focal lesions per tumor compared to 19.3 
per MDMX and 22.1 per p53TKO. In the RbTKO tumors, 
there were a total of 43 recurrent focal lesions in at least 
4/6 tumor samples (Sup. Table 7). Within the recurrent 
focal gains or losses in the RbTKO retinoblastoma model, 
we found 12 in cancer genes, including Lmo1 in 5/6 
samples; Ndrg1, Brd4, Fbxo11, and Rbm15 in 4/6 samples; 
Mdm4, Msi2, and Ezh2 in 3/6 samples. Overall, there is a 
single recurrent focal chromosomal amplification among 
all three mouse retinoblastoma models, in the Nlrp1b, a 
member of the Ced-4 family of apoptosis proteins.   
To identify single nucleotide variations (SNVs) 
and indels in the RbTKO tumors, we also performed 
whole exome sequencing of 11 tumors. Single nucleotide 
variations (SNV) were found in 63.6% (7/11) (Sup. Table 
8) and indels were found in 54.5% (6/11) of the tumors 
(Sup. Table 9). All SNVs and indels were validated by 
custom capture and Illumina sequencing. On average there 
were 3.2 somatic mutations (SNV and indels) per tumor 
in the RbTKO mouse model. There were no recurrently 
mutated genes in this cohort nor were any known cancer 
genes mutated in the 11 tumors.
Integrated Epigenetic Analysis of Mouse 
Retinoblastoma
Analyses of human retinoblastoma genome and 
epigenome uncovered few genetic lesions and identified 
epigenetic as the mechanism underlying the rapid 
progression of human retinoblastoma [6]. To determine 
if there were any epigenetically deregulated genes in 
mouse retinoblastoma that were shared with human 
retinoblastoma, we performed DNA methylation analysis 
and chromatin immunoprecipitation (ChIP) assays 
for histone marks of actively transcribed (H3K4me3 
and H3K9/14Ac) or silent chromatin (H3K9me3). We 
integrated data on gene expression, DNA methylation 
and histone marks for RbTKO tumors and P5 mouse 
retina to be able to compare our data to the previously 
published data on integrated epigenetic analysis of human 
retinoblastoma and human fetal retina. Overall, we found 
that the epigenetic landscape in mouse retinoblastoma 
was very different than for human retinoblastoma, with 
327 genes being epigenetically deregulated (Figure 
4A and Sup. Table 10). Among the 327 epigenetically 
regulated genes in mouse retinoblastoma, only 23 were 
also epigenetically deregulated in human retinoblastoma, 
17 of which change gene expression in the same direction 
(Figure 4B,C). In the mouse retinoblastoma, 11 of the 
epigenetically deregulated genes are cancer genes but 
none of those were found to be epigenetically deregulated 
in the human retinoblastomas (Sup. Table 10).  
The changes in gene expression and histone marks 
for a subset of genes were validated by real time RT-
PCR, including some of the cancer genes epigenetically 
deregulated in human retinoblastoma (SYK, ASCL1 and 
SOX2, Fig. 5A-D and data not shown). Interestingly, 
we found that SYK, a gene that is epigenetically 
upregulated in human retinoblastoma and is required for 
retinoblastoma survival, is not epigenetically deregulated 
in mouse retinoblastoma (Fig. 5B, F and J). Furthermore, 
the pathway through which it exerts its anti-apoptotic 
properties does not appear to be deregulated, as MCL1 
levels are comparable to P5 wt retinae (Fig. 5I). However, 
RbTKO mouse retinoblastomas may avoid apoptosis 
through the amplification of the MDMX gene and 
increased expression of MDMX protein suggesting a 
common mechanism of p53 pathway inactivation across 
species (Figure 4D and Fig. 5I-J).
DISCUSSION
In this study, we analyzed the species-specific 
role of RB1 in maintaining genome stability and the 
epigenetic landscape in the developing retina as it relates 
to retinoblastoma tumor initiation and progression. Like 
the human retinoblastomas, there were no recurrent 
somatic SNVs or indels in whole exome sequence analysis 
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of murine retinoblastoma. However, in contrast to human 
retinoblastoma, we found that mouse retinoblastomas 
from three different GEMMs had evidence of aneuploidy 
and chromosomal instability. We also performed the 
first integrated epigenetic analysis of a mouse tumor 
model (RbTKO) and compared the epigenome of mouse 
retinoblastoma to human retinoblastoma. We found 
that there were a significant number of epigenetically 
deregulated genes in mouse retinoblastomas and some of 
those were cancer genes but there was very little overlap 
with the human epigenome of retinoblastoma. Thus, 
these data suggest that there are differences in the relative 
contribution of chromosomal and epigenetic changes 
in human and mouse retinoblastoma despite robust 
conservation at the molecular and cellular level. There are 
important implications of these data for preclinical testing 
of new therapeutics for the treatment of retinoblastoma 
and this comparison may be relevant to other GEMMs 
of human cancer. This is especially true in cases where 
genetic lesions such as p53 mutations are engineered 
into GEMMs to promote tumor penetrance and/or 
progression even when the pathway is not mutated in the 
corresponding human tumors.
Cross-Species Comparison of Retinoblastoma
Retinoblastoma is a relatively simple tumor that 
initiates with a common genetic lesion (RB1 inactivation) 
and progresses rapidly in children. The human RB1 
gene can replace the mouse gene in vivo [35] and most 
functions of RB1 are conserved across species. Moreover, 
many features of retinal development are also conserved 
across species making retinoblastoma an ideal tumor for 
cross-species comparison. 
Previous studies on GEMMs of retinoblastoma 
have shown that there is remarkable conservation of 
gene expression signatures, histopathological features, 
neuroanatomical, neurochemical and morphological 
hallmarks across different mouse models of retinoblastoma 
with a variety of initiating genetic lesions. Importantly, all 
the tumors initiate during retinal development but progress 
at different rates. It is not known if these different rates 
are related to the mechanism of progression, the initiating 
genetic lesions or a combination of the two. 
Array CGH, karyotype analysis, SNP6.0 analysis 
and whole genome sequencing analysis have shown that 
a significant proportion of human retinoblastomas have 
near diploid genomes with few genetic lesions [6]. The 
RB1 and BCOR (13%) genes are the only genes found to 
be recurrently mutated in human retinoblastomas to date. 
The MYCN gene is the only known oncogene found to be 
focally recurrently amplified in human retinoblastomas in 
about 10% of cases [6, 36, 37]. The functional significance 
of BCOR mutations or MYCN amplifications is yet to be 
established in vivo in human retinoblastoma. In contrast 
to the genetic landscape, integrated epigenetic analysis 
showed that multiple cancer pathways were epigenetically 
deregulated in human retinoblastoma. For example, the 
SYK gene was found to be epigenetically upregulated 
in virtually all human retinoblastomas and it is required 
for tumor cell survival [6]. These data suggest that while 
genetic changes may play a role in some retinoblastomas, 
the majority of tumors progress rapidly following RB1 
inactivation as a result of epigenetic changes. Importantly, 
aneuploidy and GCRs are not a universal hallmark 
of human retinoblastomas and are not required for 
tumorigenesis.
Both human and mouse retinoblastomas had low 
rates of somatic SNVs or indels in genes. The average 
number of tier 1 mutations in human retinoblastoma was 
4 and the average number of similar mutations in RbTKO 
was 3.2. However, in contrast to human retinoblastomas, 
the 3 retinoblastoma GEMMs analyzed in this study 
showed evidence of aneuploidy and GCRs. Indeed, in the 
RbTKO strain the average number of focal CNVs was 
176 per tumor. Several of these lesions were recurrent 
such as gains in Lmo1 in 5/6 RbTKO tumors and Mdm4 
gains in 3/6 tumors. Lmo1 has been implicated as an 
oncogene in human neuroblastoma and may contribute 
to tumorigenesis in this mouse model. However, LMO1 
is not altered in human retinoblastoma at the genomic, 
epigenomic or transcriptional level. There was no evidence 
of genetic lesions in Bcor or Mycn in our mouse model of 
retinoblastoma making MDMX the only common genetic 
lesion across species in our study. 
To determine if there was cross-species conservation 
of epigenetic processes, we also performed integrated 
epigenetic analysis of the RbTKO mouse tumors and 
compared those data to the human retinoblastoma 
epigenetic landscape. From the integrated analysis, 
4009 genes are significantly deregulated in human 
retinoblastoma (2567 up- and 1442 down-regulated) 
and 3252 in mouse RbTKO tumors (1634 up- and 1618 
down-regulated). Of these, 8% (323) of the human and 
10% (327) of the mouse genes had epigenetic signatures 
that correlated with the directional changes in gene 
expression. Gene matching across species, 974 genes 
were significantly deregulated in both human and mouse 
retinoblastomas, with 682 (70%) genes changing in the 
same direction (420 up-regulated and 262 down-regulated). 
Among these 682 genes significantly deregulated in both 
species, 131 genes of the 327 mouse and 111 of the 323 
human genes are epigenetically deregulated. However, 
only 23 are epigenetically deregulated in both species (17 
in the same direction, 2.5%), indicating that while the gene 
expression changes that occur in mouse and human retinal 
tumorigenesis may be conserved, the mechanism by which 
this occurs is not. 
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Mechanisms of Retinoblastoma Progression in 
Murine Retinoblastoma 
It has been proposed from previous studies on 
mouse and human cells that perturbations in the Rb 
pathway can lead to defects in sister chromatid cohesion 
and this may contribute to aneuploidy and CIN. We found 
that human and mouse retinoblastoma cells have defects 
in sister chromatid cohesion but this does not correlate 
with aneuploidy or CIN across species or among the 
different GEMMs analyzed here. We hypothesize that 
retinoblastomas are predisposed to exhibit CIN because 
of the absence of RB1 but this is more likely to occur when 
additional stress, such as oxidative or replicative stress, 
overwhelms the cellular machinery that maintain genome 
stability. It is also possible that effects of RB1 inactivation 
on CIN and aneuploidy is cell-type specific and that 
human retinal cells lacking RB1 that have aneuploidy or 
CIN die during tumorigenesis but murine cells are more 
tolerant of such chromosomal defects [38].
One of the most striking results from our study 
related to the mechanism of tumor progression was the 
observation that the RbTKO strain had on average 176 
focal CNVs per tumor. Those tumors also had evidence 
of oxidative stress, elevated levels of DNA breaks and 
defects in their ability to repair those breaks. While human 
tumors also have evidence of oxidative stress, they do not 
result in such elevated levels of CNVs. The same was 
true for the p53TKO and MDMX GEMMs.  While all 
3 strains sustain high levels of dsDNA breaks as a result 
of oxidative stress, the inability of p53TKO and MDMX 
tumor cells to efficiently repair those breaks makes due to 
defects in the p53 pathway make them more prone to cell 
death. Thus, this may explain why the RbTKO tumors had 
a much higher rate of focal CNVs than the other strains. 
They were able to tolerate dsDNA breaks and repair many 
of them but some lesions led to chromosomal lesions. 
This may also be true for the human retinoblastomas 
that express high levels of MDMX to suppress the p53 
pathway. 
Implications for Preclinical Testing and 
Translational Research
Understanding the intra- and inter-specie differences 
is paramount when choosing the right model for the 
study of retinoblastoma. Unlike orthotopic xenograft 
models, genetic mouse models present the advantage of 
contributing to our understanding of the developmental 
processes that support tumor formation arising from a 
single cell. On the other hand, orthotopic xenografts from 
patients may more faithfully recapitulate the mechanisms 
by which gene deregulation occurs in the human disease. 
This makes orthotopic xenografts an important tool for 
target identification and target validation during pre-
clinical trials. 
The one common theme across species is 
inactivation of the Rb and p53 pathways. In the RbTKO 
tumors, they sustain Mdm4 gain and increased Mdm4 
protein expression. Therefore, targeting Mdm4 in human 
and mouse retinoblastoma may be relevant with respect 
to preclinical testing. However, there are differences 
in the SYK/MCL1 pathway. The upregulation of SYK 
found in virtually all human retinoblastomas was not 
evident in mouse retinoblastomas nor was upregulation 
of MCL1. Thus, preclinical testing using SYK or MCL1 
antagonists may not provide the most relevant results 
for translation into clinical trials using GEMMs. Both 
orthotopic xenografts and GEMMs of human cancer 
are important for translational research but each model 
must be thoroughly analyzed to understand the relevant 
pathways that contribute to tumorigenesis and the relative 
role of genomic and epigenomic changes in that process to 
accurately interpret preclinical testing data.
EXPERIMENTAL PROCEDURES
Xenografts, Mouse Models of Retinoblastoma, 
and Cell Lines
The orthotopic xenograft (SJRB001X) has been 
described previously and the whole genome has been 
sequenced [6, 9]. Two additional orthotopic xenografts 
were also used in this study (SJRB002X and SJRB004X), 
and the primary tumors that gave rise to these xenografts 
have also been described previously [9]. Severe combined 
immunodeficiency mice (SCID) were obtained from 
Jackson laboratories (B6.CB17-Prkdc<scid>SzJ).
The p107- and p130-knockout mice were 
obtained from Dr. Tyler Jacks (Massachusetts Institute 
of Technology); Chx10-Cre mice were obtained from 
Dr. Connie Cepko (Harvard Medical School); p53Lox/
Lox and RbLox/Lox mice were obtained from the Mouse 
Models of Human Cancer Consortium at the National 
Cancer Institute; MDMXTg mice were obtained from Dr. 
Guillermina Lozano (MD Anderson Cancer Center); 
and p130Lox/Lox mice were obtained from Dr. Julien Sage 
(Stanford Medical School). Mice were monitored weekly 
for signs of retinoblastoma and anterior chamber invasion. 
Moribund status was defined as the point when tumor cells 
invaded the anterior chamber and intraocular pressure 
increased to the point of imminent ocular rupture. The 
St. Jude Laboratory Animal Care and Use Committee 
approved all animal procedures.
Retinoblastoma cell lines Y79, Weri1, and RB355 
were cultured in RPMI medium (Lonza RPMI-1640) 
supplemented with 10% fetal bovine serum (Equitech 
Bio.), penicillin, streptomycin, and glutamate (Gibco). 
Cells were passaged every 3 to 4 days or when they 
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reached 70% to 80% confluence. At the time of passage, 
cells were split to 20% confluence. BJ cells were grown 
in EMEM supplemented with 10% FBS; SJmRBL8 cells 
were grown in RPMI supplemented with 10% FBS; 
and Brca2/p53-deficient cells were grown in DMEM 
supplemented with 10% FBS. 
Sister Chromatid Analysis and Cytogenetics
Tumors were mechanically dissociated into a single-
cell suspension in RPMI cell culture media with 10% FBS. 
Retinoblastoma cell lines were cultured to 60%–70% 
confluency. Cells were treated with colcemid (18ng/mL) 
for 4 hrs or 20 hrs at 37 °C. Cells were centrifuged at 
900 RPM for 5 minutes. The cell pellet was resuspended 
in 0.075M KCl for 8 minutes at room temperature and 
then centrifuged at 600 RPM for 5 minutes, resuspended 
in 3:1 fixative (3 parts methanol: 1 part acetic acid), and 
incubated for 15 minutes at room temperature. The cells 
were added to one end of a glass slide (in upright position) 
in a droP-wise manner by using a Pasteur pipette, allowing 
the cells to migrate down the slide. The slides were dried 
at room temperature and then stained with DAPI (80 µg/
mL). Sister chromatid and spectral karyotyping (SKY) of 
chromosomes analyses were performed as described in 
Supplemental Experimental Procedures.
Immunostaining
Cells were plated on poly-L-lysine– (Sigma) 
coated slides for 30 minutes and then fixed in 4% 
paraformaldehyde (Sigma). An anti-TP53BP1 antibody 
(Bethyl Labs; 1:10,000) was used followed by a 
biotinylated anti-rabbit secondary (Vector Labs; 1:500), 
VectaStain ABC (Vector Labs) and Cyanine 3 tyramide 
reagent (PerkinElmer) with DAPI counterstaining. 
Human Retinoblastoma Tissue Microarray 
Analysis
We generated a human retinoblastoma tissue 
microarray with 90 different tumor samples and 2 cores 
per tumor. The immunohistochemical staining was 
performed per the standard protocol on 4-μm sections 
of formalin-fixed, paraffinized tissue microarrays with a 
commercially available 53BP1 antibody (Cell Signaling; 
1:100) on a Ventana automated immunostainer by using 
heat-induced epitope retrieval with EDTA buffer at pH 8.0 
and the UltraView detection system. A “normal pattern” 
of expression was characterized by a homogenous nuclear 
staining. Complete loss or significant reduction in the 
intensity of nuclear staining was marked as “reduced” or 
“lost”, respectively. A clumped, dot-like nuclear staining 
was regarded as an “abnormal pattern” of expression, 
reflecting the activation of the DNA damage response to 
DNA double-strand breaks. When the abnormal pattern 
was observed in most of the tumor cells, it was marked 
as “extensive”; when it was present in only some of the 
tumor cells, it was marked as “focal”.
Mouse Retinoblastoma Tissue Analysis
The immunohistochemical staining for the 3 
retinoblastoma mouse models was performed on 5 
different tumor samples per condition on 4-μm sections 
of formalin-fixed, paraffinized tissue. The commercially 
available TP53BP1 antibody (Bethyl Labs; 1:800) was 
used on a Bond Max (Leica) automated immunostainer 
by using heat-induced epitope retrieval with ER1 buffer 
(Leica) and the Bond Polymer detection system (Leica).
Comet Assay
Alkaline single cell gel electrophoresis was 
performed based on the method of Singh et al[39]. 
Briefly, 100 μL of cells (100,000 cells/ml) suspended in 
PBS were mixed with 100 μL of 0.5% low melting point 
agarose (Sigma) and layered on CometSlides (Trevigen). 
The mixture was allowed to solidify at 4°C for 15 min 
on a metal plate. Cells were then incubated overnight at 
4°C in fresh lysis buffer (2.5 M NaCl, 100 mM EDTA, 
1% Triton, and 10 mM Tris, adjusted to pH 10 with 
NaOH). Following cell lysis, the slides were incubated 
at room temperature with fresh alkali buffer (300 mM 
NaOH, 1 mM EDTA, pH >13) for 40 min to allow DNA 
denaturation and unwinding. Then, the slides were run 
in chilled alkali buffer (300 mM NaOH, 1 mM EDTA, 
pH >13) at a constant electric current of 300 mA for 23 
min. After electrophoresis, the slides were neutralized 
with three 5 min washes in 0.4 mol/L Tris-HCl (pH 7.4). 
Finally, the slides were fixed in 100% ethanol for 5 min 
and stored in the dark at room temperature. Immediately 
prior to imaging, comet slides were hydrated and stained 
by exposure to 1 mg/mL ethidium bromide for 15 min. 
Comets were analyzed using fluorescence based digital 
imaging system. Tail moments were calculated using 
Comet Assay Software Project (Casp) imaging software.
DNA Methylation Analysis
DNA methylation analysis was performed using 
NimbleGen DNA methylation microarray services and 
the samples were prepared following NimbleGen’s 
recommendations. Genomic DNA was extracted using 
the DNeasy Kit (Qiagen) following the manufacturing 
instructions including the RNeaseA treatment. 6µg of 
high-quality genomic DNA was digested with 24U of MseI 
(New England BioLabs) overnight at 37°C supplemented 
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with 100ng/µl BSA and the reaction was stopped by 
heating the samples for 20 min at 65°C.  The digested 
DNA was purified using QIAquick PCR Purification Kit 
(Qiagen) and optimal fragment size of 200-1000 bp was 
verified on a 2% agarose gel. 1.25µg of digested DNA was 
brought to a final volume of 300 µl in TE buffer (10mM 
Tris HCl, pH7.5; 1 mM EDTA), heat-denatured for 10 
min at 95°C and immediately cooled on ice for 5 min. As 
control (input) DNA, 60µl of this sample were removed 
and stored at -20°C. To the remaining 240 µl of DNA, 
60µl of 5X IP buffer (50mM Na-Phosphate, pH 7.0; 0.7 
M NaCl; 0.25% Triton X-100) and 1 µg of monoclonal 
mouse anti 5-methyl cytidine (Abcam) was added and 
incubated at 4°C overnight. After overnight incubation, 
48µl of a 50% slurry of Protein A agarose beads (24µl 
pre-washed beads resuspended in 24l of 1X IP buffer; 
Invitrogen) was added and incubated for 2 hr at 4°C. 
After washing 3 times with 1X IP buffer, the beads were 
digested overnight at 55°C in 250µl of digestion buffer 
(50 mM Tris HCl pH 8.0, 10 mM EDTA, 0.5% SDS) and 
7µl Proteinase K mix (10 mg/ml). Input and IP DNA were 
finally phenol-chloroform purified.
Chromatin Preparation and ChIP-on-chip
ChIP was performed by using the MAGnify 
Chromatin Immunoprecipitation System (Invitrogen) 
with some modifications. Retinae chromatin was prepared 
by incubating the retinae in 1% formaldehyde for 10 
min at room temperature before washing them in PBS. 
Cross-linking was stopped by adding 1X glycine for 5 
min. Retinae were then washed with PBS, dissolved in 
lysis buffer containing protease inhibitors (20,000 cells/
μL), and incubated on ice for 30 min. Extracts were 
sonicated by using the Bioruptor (Diagenode) at high 
power until DNA fragments of 300–500 bp were formed. 
Sonicated chromatin was diluted 1:10 in dilution buffer. 
The immuno-complexes were precipitated with antibodies 
against polII (sc-899, Santa Cruz Biotechnologies), 
H3K9/14ac (49-1010, Invitrogen), H3K4me3 (49-1005, 
Invitrogen), H3K9me3 (49-1008, Invitrogen), or normal 
serum IgG (ab46540, Abcam). Precipitated complexes 
were reverse cross-linked, and proteins were digested 
with proteinase K (Invitrogen) overnight at 65 °C. Purified 
DNA was used for PCR and ChIP-on-chip analysis. ChIP 
experiments were run in triplicate. To obtain sufficient 
DNA for ChIP-on- chip hybridization, purified ChIP DNA 
was amplified by using the GenomePlex WGA kit (Sigma-
Aldrich). Amplified DNA was analyzed by using 385K 
RefSeq Promoters Array (Roche Nimblegen).
Gene Expression Arrays
Gene expression arrays were analyzed as described 
previously [9].
FACS Analysis of DNA Content 
Tumors were dissected in RPMI cell culture media 
containing 10% FBS and mechanically dissociated 
into a single cell suspension using a 1000µl pipette. 
Retinoblastoma cell lines were harvested at 70% 
confluency. 500,000 cells from the tumor cell suspension 
and cell lines were centrifuged at 1,500 RPM for 7 minutes 
at room temperature. Cell pellets were washed with PBS 
and centrifuged again. Cell pellets were resuspended in 
0.5ml of propidium iodide solution (0.05 mg/ml propidium 
iodide, 0.1% (w/v) sodium citrate, 0.1% (v/v) Triton 
X-100).To remove RNA, 10µl of ribonuclease A (0.2 mg/
ml (Calbiochem 556746) in Tris-HCl pH7.5/15mM NaCl; 
DNAse was heat inactivated for 15 minutes) was added to 
the samples for 30 minutes at room temperature and then 
transferred to ice.  Samples were filtered through 40µm 
nylon mesh (Small Parts, Inc.) prior to flow cytometry 
(BD Biosciences Laser II).  
AGDEX analysis
Agreement of differential expression within and 
cross-species retinoblastoma genomics was conducted 
as described previously [15, 40]. The Affymetrix 430v2 
array was used to profile the expression of 45101 
probe-sets for 27 RBTKO, 27 MDMX, 26 p53TKO 
retinoblastoma samples, and 6 wt (p5) control samples. 
Additionally, the Affymetrix U133+2 array was used to 
profile the expression of 54 675 probe-sets for 57 human 
retinoblastoma samples and 8 control samples (fetal retina, 
FW18). The expression data were normalized with the 
MAS 5.0 algorithm.
We used the Affymetrix best-match dataset 
(available from www.affymetrix.com) to define 79361 
pairs of ortholog-matched probe-sets across the two arrays. 
The best-match dataset was used to define the gene-sets 
for the mouse array probesets. The 1454 biological process 
gene-set definitions from the geneset enrichment analysis 
website (www.broadinstitute.org/gsea) were used for the 
U133+2 array.
Adaptive permutation with Bmin=100 and 
Bmax=10000 was used to compute P-values for gene-
set statistics. P-values for individual probe-set statistics 
and the genome-wide dop and cosine statistics were 
determined using 10000 permutations.
Kruskal–Wallis test was used to compare three 
mouse strains (RBTKO, p53TKO and MDMX) and 
Wilcoxon Rank-sum test to compare two groups of 
RBTKO versus p53TKO, RBTKO versus MDMX, and 
MDMX versus p53TKO.
ACKNOWLEDGMENTS
We thank Deanna Naeve for help with exome 
Oncotarget 2013; 4: 844-859858www.impactjournals.com/oncotarget
sequencing. Michael Edmonson, Donald Yergeau 
and Xiang Chen for help with MiSeq validation. This 
work was supported in part by Cancer Center Support 
(CA21765) from the NCI and grants to M.A.D from the 
NIH (EY014867 and EY018599), the American Cancer 
Society, and Research to Prevent Blindness Foundation; 
and the American Lebanese Syrian Associated Charities 
(ALSAC). M.A.D. is a Howard Hughes Medical Institute 
Early Career Scientist. The authors have no conflict of 
interests to disclose.
REFERENCES
1. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport 
JM, Albert DM and Dryja TP. A human DNA segment with 
properties of the gene that predisposes to retinoblastoma 
and osteosarcoma. Nature. 1986; 323(6089):643-646.
2. Manning AL, Longworth MS and Dyson NJ. Loss of 
pRB causes centromere dysfunction and chromosomal 
instability. Genes Dev. 2010; 24(13):1364-1376.
3. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos 
M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, 
Lowe SW and Cordon-Cardo C. Rb inactivation promotes 
genomic instability by uncoupling cell cycle progression 
from mitotic control. Nature. 2004; 430(7001):797-802.
4. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, 
Piovesan B, Marrano P, Corson TW, Eagle RC, Jr., Squire 
JA and Gallie BL. Loss of RB1 induces non-proliferative 
retinoma: increasing genomic instability correlates with 
progression to retinoblastoma. Hum Mol Genet. 2008; 
17(10):1363-1372.
5. Ferreira R, Naguibneva I, Pritchard LL, Ait-Si-Ali S 
and Harel-Bellan A. The Rb/chromatin connection and 
epigenetic control: opinion. Oncogene. 2001; 20(24):3128-
3133.
6. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, 
Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, 
Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, et al. A 
novel retinoblastoma therapy from genomic and epigenetic 
analyses. Nature. 2012; 481(7381):329-334.
7. Zhang J, Schweers B and Dyer MA. The first knockout 
mouse model of retinoblastoma. Cell Cycle. 2004; 3(7):952-
959.
8. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller 
C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, 
Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, 
Mendrysa SM, et al. Inactivation of the p53 pathway in 
retinoblastoma. Nature. 2006; 444(7115):61-66.
9. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan 
R, Bradley C, Krafcik F, Rodriguez-Galindo C, Wilson M, 
Xiong S, Lozano G, Sage J, Fu L, Louhibi L, Trimarchi 
J, Pani A, et al. Coexpression of normally incompatible 
developmental pathways in retinoblastoma genesis. Cancer 
Cell. 2011; 20(2):260-275.
10. Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, 
Egorin M, Stewart C and Dyer MA. Topotecan combination 
chemotherapy in two new rodent models of retinoblastoma. 
Clin Cancer Res. 2005; 11(20):7569-7578.
11. Nemeth KM, Federico S, Carcaboso AM, Shen Y, 
Schaiquevich P, Zhang J, Egorin M, Stewart C and Dyer 
MA. Subconjunctival carboplatin and systemic topotecan 
treatment in preclinical models of retinoblastoma. Cancer. 
2011; 117(2):421-434.
12. Brennan RC, Federico S, Bradley C, Zhang J, Flores-
Otero J, Wilson M, Stewart C, Zhu F, Guy K and Dyer 
MA. Targeting the p53 pathway in retinoblastoma with 
subconjunctival Nutlin-3a. Cancer Res. 2011; 71(12):4205-
4213.
13. Fukasawa K, Wiener F, Vande Woude GF and Mai S. 
Genomic instability and apoptosis are frequent in p53 
deficient young mice. Oncogene. 1997; 15(11):1295-1302.
14. Norimura T, Nomoto S, Katsuki M, Gondo Y and Kondo 
S. p53-dependent apoptosis suppresses radiation-induced 
teratogenesis. Nat Med. 1996; 2(5):577-580.
15. Pounds S, Cao X, Cheng C, Yang JJ, Campana D, Pui 
CH, Evans WE and Relling MV. Integrated analysis of 
pharmacologic, clinical and SNP microarray data using 
Projection Onto the Most Interesting Statistical Evidence 
with Adaptive Permutation Testing. Int J Data Min 
Bioinform. 2011; 5(2):143-157.
16. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao 
C, Finkelstein D, Qu C, Pounds S, Ellison DW, Gilbertson 
RJ and Roussel MF. A mouse model of the most aggressive 
subgroup of human medulloblastoma. Cancer Cell. 2012; 
21(2):168-180.
17. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, 
Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright 
WE. Extension of life-span by introduction of telomerase 
into normal human cells. Science. 1998; 279(5349):349-
352.
18. Laurie N, Mohan A, McEvoy J, Reed D, Zhang J, 
Schweers B, Ajioka I, Valentine V, Johnson D, Ellison D 
and Dyer MA. Changes in retinoblastoma cell adhesion 
associated with optic nerve invasion. Mol Cell Biol. 2009; 
29(23):6268-6282.
19. McFall RC, Sery TW and Makadon M. Characterization 
of a new continuous cell line derived from a human 
retinoblastoma. Cancer Res. 1977; 37(4):1003-1010.
20. Squire J, Gallie BL and Phillips RA. A detailed analysis 
of chromosomal changes in heritable and non-heritable 
retinoblastoma. Hum Genet. 1985; 70(4):291-301.
21. Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova 
EV, Pan Y, Nezi L, Protopopov A, Chowdhury D and 
Pellman D. DNA breaks and chromosome pulverization 
from errors in mitosis. Nature. 2012; 482(7383):53-58.
22. Reid TW, Albert DM, Rabson AS, Russell P, Craft J, 
Chu EW, Tralka TS and Wilcox JL. Characteristics of an 
established cell line of retinoblastoma. J Natl Cancer Inst. 
Oncotarget 2013; 4: 844-859859www.impactjournals.com/oncotarget
1974; 53(2):347-360.
23. Ganem NJ, Godinho SA and Pellman D. A mechanism 
linking extra centrosomes to chromosomal instability. 
Nature. 2009; 460(7252):278-282.
24. Iovino F, Lentini L, Amato A and Di Leonardo A. RB acute 
loss induces centrosome amplification and aneuploidy in 
murine primary fibroblasts. Molecular cancer. 2006; 5:38.
25. Amato A, Lentini L, Schillaci T, Iovino F and Di Leonardo 
A. RNAi mediated acute depletion of retinoblastoma 
protein (pRb) promotes aneuploidy in human primary cells 
via micronuclei formation. BMC cell biology. 2009; 10:79.
26. Ono T, Fang Y, Spector DL and Hirano T. Spatial and 
temporal regulation of Condensins I and II in mitotic 
chromosome assembly in human cells. Molecular biology 
of the cell. 2004; 15(7):3296-3308.
27. Kenney RD and Heald R. Essential roles for cohesin in 
kinetochore and spindle function in Xenopus egg extracts. 
Journal of cell science. 2006; 119(Pt 24):5057-5066.
28. Samoshkin A, Arnaoutov A, Jansen LE, Ouspenski I, 
Dye L, Karpova T, McNally J, Dasso M, Cleveland DW 
and Strunnikov A. Human condensin function is essential 
for centromeric chromatin assembly and proper sister 
kinetochore orientation. PLoS One. 2009; 4(8):e6831.
29. McKinnon PJ and Caldecott KW. DNA strand break repair 
and human genetic disease. Annu Rev Genomics Hum 
Genet. 2007; 8:37-55.
30. Jeggo PA and Lobrich M. DNA double-strand breaks: their 
cellular and clinical impact? Oncogene. 2007; 26(56):7717-
7719.
31. Hakem R. DNA-damage repair; the good, the bad, and the 
ugly. Embo J. 2008; 27(4):589-605.
32. Frappart PO, Lee Y, Lamont J and McKinnon PJ. 
BRCA2 is required for neurogenesis and suppression of 
medulloblastoma. Embo J. 2007; 26(11):2732-2742.
33. D’Angiolella V, Santarpia C and Grieco D. Oxidative 
stress overrides the spindle checkpoint. Cell Cycle. 2007; 
6(5):576-579.
34. McBride TJ, Schneider JE, Floyd RA and Loeb LA. 
Mutations induced by methylene blue plus light in single-
stranded M13mp2. Proc Natl Acad Sci U S A. 1992; 
89(15):6866-6870.
35. Bignon YJ, Chen Y, Chang CY, Riley DJ, Windle JJ, 
Mellon PL and Lee WH. Expression of a retinoblastoma 
transgene results in dwarf mice. Genes Dev. 1993; 
7(9):1654-1662.
36. Lee WH, Murphree AL and Benedict WF. Expression and 
amplification of the N-myc gene in primary retinoblastoma. 
Nature. 1984; 309(5967):458-460.
37. Squire J, Goddard AD, Canton M, Becker A, Phillips RA 
and Gallie BL. Tumour induction by the retinoblastoma 
mutation is independent of N-myc expression. Nature. 
1986; 322(6079):555-557.
38. Manning AL and Dyson NJ. pRB, a tumor suppressor with 
a stabilizing presence. Trends in cell biology. 2011.
39. Singh NP, McCoy MT, Tice RR and Schneider EL. A 
simple technique for quantitation of low levels of DNA 
damage in individual cells. Exp Cell Res. 1988; 175(1):184-
191.
40. Pounds S, Gao CL, Johnson RA, Wright KD, Poppleton H, 
Finkelstein D, Leary SE and Gilbertson RJ. A procedure 
to statistically evaluate agreement of differential expression 
for cross-species genomics. Bioinformatics. 2011; 
27(15):2098-2103.
